Obesity management among patients with type 2 diabetes and prediabetes: a focus on lifestyle modifications and evidence of antiobesity medications

References

• Bays HE, Seger JC, Primack C, et al. Obesity Algorithm, presented by the Obesity Medicine Association. 2016-2017. [cited 2017 Mar 3]. Available from: www.obesityalgorithm.org
   Google Scholar
• The GBD 2015 Obesity Collaborators. Health effect of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017 Jun 12. Epub ahead of print. DOI: 10.1056/NEJMoa1614362.
   Web of Science ®Google Scholar
• Ogden CL, Carroll MD, Fryar CD, et al. Prevalence of obesity among adults and youth: United States, 2011–2014. NCHS data brief, no 219. Hyattsville, MD: National Center for Health Statistics; 2015.
   Google Scholar
• Center for Diseases Control Division of Diabetes Translation. United States Diabetes Surveillance System. [cited 2017 Mar 3]. Available from: http://www.cdc.gov/diabetes/data.
   Google Scholar
• Statistics about Diabetes. American Diabetes Association. 2015 May 18. [Updated 2017 Apr 5; cited 2017 Jun 2]. Available from: http://www.diabetes.org/diabetes-basics/statistics/.
   Google Scholar
• Obesity and overweight: Fact sheet. World Health Organization. 2016 Jun. [cited 2017 Jun 2]. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/
   Google Scholar
• Stefan N, Haring H, Hu FB, et al. Metabolically healthy obesity: epidemiology, mechanisms and clinical implications. Lancet Diabetes Endocrinol. 2013 Oct;1(2):152–162.
   PubMed Web of Science ®Google Scholar
• Frühbeck G, Toplak H, Woodward E, et al. Executive committee of the European Association for the study of obesity. Obesity: the gateway to ill health - an EASO position statement on a rising public health, clinical and scientific challenge in Europe. Obes Facts. 2013;6(2):117–120.
   PubMed Web of Science ®Google Scholar
• Gómez-Ambrosi J, Silva C, Galofré JC, et al. Body adiposity and type 2 diabetes: increased risk with a high body fat percentage even having a normal BMI. Obesity (Silver Spring). 2011 Jul;19(7):1439–1444.
   PubMed Web of Science ®Google Scholar
• Jensen MD, Ryan DH, Apovian CM. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. J Am Coll Cardiol. 2014;63:2985–3023.
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Obesity in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Heart, Lung, and Blood Institute; 1998. (Report no. 98-4083).
   Google Scholar
• Seger JC, Horn DB, Westman EC, et al. American Society of Bariatric Physicians Obesity Algorithm: Adult Adiposity Evaluation and Treatment 2013. [cited 2017 Jun 2]. Available from: www.obesityalgorithm.org.
   Google Scholar
• Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016 Jul;22Suppl 3:1–203. Epub 2016 May 24. DOI:10.4158/EP161365.GL.
   Web of Science ®Google Scholar
• Bray GA, Fruhbeck G, Ryan DH, et al. Management of obesity. Lancet. 2016 May 7;387(10031):1947–1956.
   PubMed Web of Science ®Google Scholar
• Volek JS, Phinney SD, Forsythe CE, et al. Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low fat diet. Lipids. 2009;44:297–309.
   PubMed Web of Science ®Google Scholar
• Foster GD, Wyatt HR, Hill JO, et al. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. Ann Intern Med. 2010;153:147–157.
   PubMed Web of Science ®Google Scholar
• Strasser B. Physical activity in obesity and metabolic syndrome. Ann N Y Acad Sci. 2013;1281:141–159.
   PubMed Web of Science ®Google Scholar
• Carlson SA, Fulton JE, Schoenborn CA, et al. Trend and prevalence estimates based on the 2008 physical activity guidelines for Americans. Am J Prev Med. 2010;39:305–313.
   PubMed Web of Science ®Google Scholar
• Garland T, Schutz H, Chappell MA, et al. The biological control of voluntary exercise, spontaneous physical activity and daily energy expenditure in relation to obesity: human and rodent perspectives. J Exp Biol. 2011;214:206–229.
   PubMed Web of Science ®Google Scholar
• Ng SW, Popkin BM. Time use and physical activity: a shift away from movement across the globe. Obes Rev. 2012;13:659–680.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association - standards of medical care in diabetes, 2017. Diabetes Care. 2017;40(Supp 1):S1–S134.
   PubMedGoogle Scholar
• Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet. 2009;14:1677–1686.
   Web of Science ®Google Scholar
• Tuomilehto J, Lindström J, Eriksson JG, et al. Finnish Diabetes Prevention Study Group Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–1350.
   PubMed Web of Science ®Google Scholar
• Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: A 20-year follow-up study. Lancet. 2008 May;371(9626):1783–1789.
   PubMed Web of Science ®Google Scholar
• Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle interventions for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2014 Jun;2(6):474–480.
   PubMed Web of Science ®Google Scholar
• The Look AHEAD Research Group. Cardiovascular effects on lifestyle interventions in type 2 diabetes. N Engl J Med. 2013;369:145–154.
   PubMed Web of Science ®Google Scholar
• Look AHEAD Research Group. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomized clinical trial. Lancet Diabetes Endocrinol. 2016 Nov;4(11):913–921.
   PubMed Web of Science ®Google Scholar
• Belviq (lorcaserin) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; 2014 Dec.
   Google Scholar
• Belviq XR (lorcaserin) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; 2016 Jul.
   Google Scholar
• Qsymia (phentermine/topiramate) [prescribing information]. Mountain View, CA: Vivus, Inc; 2014 Oct.
   Google Scholar
• Contrave (naltrexone and bupropion) [prescribing information]. La Jolla, CA: Orexigen Therapeutics Inc.; 2016 Sep.
   Google Scholar
• Saxenda (liraglutide) [prescribing information]. Plainsboro, NJ: Novo Nordisk; 2016 Sep.
   Google Scholar
• Food and Drug Administration. Guidance for industry: developing products for weight management (draft guidance). [cited 2017 Jun 2]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071612.pdf.
   Google Scholar
• Cefalu WT, Bray GA, Home PD, et al. Advances in the science, treatment, and prevention of the disease of obesity: reference from a diabetes care Editor’s expert forum. Diabetes Care. 2015;38:1567–1582.
   PubMed Web of Science ®Google Scholar
• Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010 Jul 15;363(3):245–256.
   PubMed Web of Science ®Google Scholar
• Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM Trial. J Clin Endocrinol Metab. 2011;96:3067–3077.
   PubMed Web of Science ®Google Scholar
• O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20:1426–1436.
   PubMed Web of Science ®Google Scholar
• Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–1352.
   PubMed Web of Science ®Google Scholar
• Hollander P, Gupta AK, Plodkoski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022–4029.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes randomized clinical trial. Jama. 2015;314(7):687–699.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K. et al. A randomized controlled trial of 3.0 liraglutide in weight management. N Engl J Med. 2015;373:11–22.
   PubMed Web of Science ®Google Scholar
• MacDaniels JS, Schewartz TL. Effectiveness, tolerability, and practical application of the newer generation anti-obesity medications. Drugs Context. 2016;5:212291.
   PubMedGoogle Scholar
• Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330–342.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297–308.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Ryan DH, Bohannon NJV, et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care. 2014 Dec;37(12):3309–3316.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19:110–120.
   PubMed Web of Science ®Google Scholar
• Greenway FL, Fuijoka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595–605.
   PubMed Web of Science ®Google Scholar
• Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21:935–943.
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski ER, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016;315(10):990–1004.
   PubMed Web of Science ®Google Scholar
• Astrup A, Rossner S, Gaal LV, et al. Effects of liraglutide in the treatment of obesity: a randomized, double-blind, placebo-controlled study. Lancet. 2009;374:1606–1616.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes. 2013;37:1443–1451.
   PubMed Web of Science ®Google Scholar
• Le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: randomised, double-blind trial. Lancet. 2017;389:1399–1409.
   PubMed Web of Science ®Google Scholar
• Blackman A, Foster GD, Zammit G. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016 Aug;40(8):1310–1319.
   PubMed Web of Science ®Google Scholar
• Fruhbeck G. Bariatric and metabolic surgery: a shift in eligibility and success criteria. Nat Rev Endocrinol. 2015 Aug;11(8):465–477.
   PubMed Web of Science ®Google Scholar
• Moncada R, Landecho MF, Fruhbeck G. Metabolic surgery enters the T2DM treatment algorithm. Trends Endocrinol Metab. 2016 Oct;27(10):678–680.
   PubMed Web of Science ®Google Scholar